ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low
While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low
What's Your Reaction?
